ABSTRACT AMP-activated protein kinase (AMPK) is a metabolic stress-sensing kinase. We previously showed that glucose deprivation induces autophosphorylation of AMPKβ at threonine-148 (Thr-148), which prevents the binding of AMPK to glycogen. Furthermore, in MIN6 cells, AMPKβ1 binds to R6 (PPP1R3D), a glycogen-targeting subunit of protein phosphatase 1 (PP1), thereby regulating the glucose-induced inactivation of AMPK. Here, we further investigated the interaction of R6 with AMPKβ and the possible dependency on Thr-148 phosphorylation status. Yeast two-hybrid analyses and co-immunoprecipitation of the overexpressed proteins in HEK293T cells revealed that both AMPKβ1 and β2 wild-type (WT) isoforms bind to R6. The AMPKβ/R6 interaction was stronger with the muscle-specific β2-WT and required association with the substrate-binding motif of R6. When HEK293T cells or C2C12 myotubes were cultured in high-glucose medium, AMPKβ2-WT and R6 weakly interacted. In contrast, glycogen depletion significantly enhanced this protein interaction. Mutation of AMPKβ2 Thr-148 prevented the interaction with R6 irrespective of the intracellular glycogen content. Treatment with the AMPK activator oligomycin enhanced AMPKβ2/R6 interaction in conjunction with increased Thr-148 phosphorylation in cells grown in low glucose medium. These data are in accordance with R6 binding directly to AMPKβ2 when both proteins detach from the diminishing glycogen particle, which is simultaneous to increased AMPKβ2 Thr-148 autophosphorylation. Such model points to a possible control of AMPK by PP1-R6 upon glycogen depletion in muscle.
The mouse skeletal muscle cell line C2C12 was kindly provided by Dr. R.C. Langen (Maastricht University, The Netherlands). C2C12 cells were continuously cultured to approximately 80 % confluence in DMEM with high glucose (25 mM) (Gibco), supplemented with 10 % (v/v) iFCS (Bodinco BV, Alkmaar, The Netherlands) and 1 % penicillin/streptomycin (Invitrogen). For differentiation into myotubes, myocytes (75 -85 % confluence) were further grown in differentiation medium (DMEM 25 mM glucose (Gibco), supplemented with 2 % heat-inactivated horse serum (Invitrogen, Life Technologies) and 1 % penicillin/streptomycin (Invitrogen) for 4 -5 days. Subsequently, cells were used in the corresponding experiments. In order to induce glycogen depletion, myotubes were maintained in low glucose medium (DMEM 3 mM glucose, supplemented with 2 % iFCS), for 16 h. In order to activate AMPK, myotubes were maintained in high or low glucose for 16 hours as described above, and subsequently treated with oligomycin (5 μM, Sigma) for 30 min.
Retroviral infections
In order to study protein-protein interactions in C2C12 myotubes, growing cells were infected with FlAsH-tagged AMPKβ2-WT or -T148D, or FLAG-tagged R6 retrovirus. Briefly, retroviral systems and Phoenix helper-free retrovirus producer cell lines were used as published before (26) (27) (28) . Amphotropic retroviral supernatants were produced as previously described (22) . Briefly, 24 -48 h after calcium phosphate/DNA transfection of producer cells, supernatants were harvested, filtered (0.45 micron filters; Corning, Germany) and used for infection of C2C12 cells in presence of 4 µg/ml polybrene (Sigma). For infections, cells were incubated with virus particles for 6 -8 h and then allowed to recover for 48 h on fresh medium, before selection pressure was applied. Stably infected cells were selected 2 days postinfection with 4 μg/ml puromycin for 36 -48 h preceding experiments.
Immunoprecipitation and Western blotting
Immunoprecipitation procedures were performed as previously described (22) . Briefly, exogenous myc-AMPKα1 was immunoprecipitated using anti-myc-tag antibody (9B11, Cell Signaling Technology, Beverly, MA), exogenous R6 was immunoprecipitated using anti-FLAG-tag antibody (F3165, Sigma), and endogenous AMPK was immunoprecipitated using a combination of AMPKα1 and AMPKα2 antibodies raised in sheep (kindly provided by Prof. dr. G. Hardie), followed by incubation with protein G-Sepharose beads (GE Healthcare). Western blot analysis was carried out using the following primary antibodies: myc-tag, tAMPKα, AMPKβ1, AMPKβ2, phospho-AMPK-T172 (all from Cell Signaling Technology, Beverly, MA), FLAG-tag (F3165, Sigma), R6 (AP13440a, Abgent), and phospho-AMPKβ2-T148 (22) . R6 was detected using FLAG-tag (F3165, Sigma), unless otherwise stated. Detection was performed according to its primary antibody using anti-rabbit (Cell Signaling Technology) and anti-mouse (Dako) horse-radish peroxidase (HRP)-conjugated secondary antibodies, followed by chemiluminescence.
In order to investigate the role of glycogen, myc-AMPKα1 was immunoprecipitated using the anti-myc-tag antibody after the addition of the glycogen-mimic β-cyclodextrin (5 mM, Sigma) for 1 h at 4 °C. Subsequently, immune complexes were electrophoresed by SDS-PAGE and analyzed by Western blot analysis, as described above.
Biochemical intracellular glycogen measurement
Intracellular glycogen content was measured, as previously described (22) . Briefly, HEK293T cells (nontransfected or transfected) or stably-infected C2C12 myotubes were lysed in potassium hydroxide (30 %) and boiled at 70 °C for 30 min. Subsequently, samples were cooled to 25 °C before sodium sulfate (6 %, w/v) and EtOH (99.5 %, v/v) were added at a 1:1:3 ratio. After thorough mixing, samples were rotated top-over-top at 4 °C for 30 -60 min. The precipitate was collected by centrifugation at 5000 rpm (Eppendorf Centrifuge 5415 R) for 5 min at 4 °C. To hydrolyze glycogen, pellets were dissolved in 1 M HCl and boiled at 100 °C for 2 h. Samples were cooled before neutralization using 2 M NaOH. Hydrolysates were used for glucose determination using a glucose (GO) assay kit (Sigma), according to the manufacturer's instructions.
Determination of glucose uptake
The glucose uptake protocol was adapted from earlier work (29) . Briefly, stably infected C2C12 myotubes were incubated with the uptake buffer containing deoxy-D-glucose (4 μM), with tracer amounts of 3 Hlabelled 2-deoxy-D-glucose, for 10 min. Surplus substrate was removed by washing the cells with ice-cold uptake buffer and cells were lysed in 0.1 N sodium hydroxide. Incorporated glucose was assessed by scintillation counting of 3 H in lysates.
Preparation of skeletal muscle tissue homogenates
Gastrocnemius muscle was taken from one female wild type C57/BL6 mouse of the regular Maastricht University breeding program. After sacrifice by carbon dioxide inhalation and cervical dislocation, tissues were freeze clamped between aluminum tongs precooled in liquid nitrogen and stored at -80°C until analysis. Muscle extract was prepared essentially as previously described (30) . Briefly, the tissue sample was extracted in SET buffer (250 mM Sucrose, 2 mM EDTA, 10 mM Tris, pH 7.4) in the presence of protease and phosphatase inhibitors (Complete and PhosStop; Roche) by homogenization and ultrasound treatment, followed by centrifugation. Supernatant was used for immunoprecipitation (see above) using the indicated antibodies.
Yeast two-hybrid (Y2H) analyses
Yeast two-hybrid analysis was performed as previously described (20, 24) . Briefly, interaction analysis using yeast THY-AP4 strain (MATa, ura3, leu2, lexA::lacZ::trp1, lexA::HIS3, lexA::ADE2) cotransformed with the indicated combination of plasmids (see above). Transformants were grown in selective 4 % glucose synthetic complete medium lacking the corresponding supplements to maintain selection for plasmids. The strength of the interaction was determined by measuring β-galactosidase activity in permeabilized yeast cells and expressed in Miller units. In all Y2H analyses similar protein levels were obtained from the expression constructs, as verified in the crude extracts from the different yeast transformants.
Statistical analysis
All bar graph data are presented as mean ± S.E.M., unless otherwise stated. Statistical differences were evaluated using unpaired Student's t test and statistical analysis software Prism 4 (GraphPad Software, Inc.). P values equal to or less than 0.05 were considered statistically significant.
RESULTS

R6 preferentially interacts with AMPKβ2
We previously demonstrated that R6 (PPP1R3D), one of the glycogen-targeting subunits of the protein phosphatase 1 (PP1), physically interacts with AMPKβ1 in MIN6 pancreatic β cells (20). To verify AMPKβ1/R6 interaction in HEK293T cells, we overexpressed myc-tagged AMPK heterotrimers (myc-α1, β1-mCherry, γ1), together with FLAG-tagged R6 (FLAG-R6) or empty vector control (EV). Physical interaction between AMPKβ1 and R6 was assessed by immunoprecipitation (IP) of AMPK from cells that were routinely cultured under glucose-rich conditions (25 mM glucose) (Fig. 1A) . Pull-down of myc-AMPKα1 resulted in co-immunoprecipitation of both mCherry-tagged AMPKβ1 (65 kD) and FLAG-tagged R6, indicating formation of the heterotrimeric AMPK complex and the interaction with R6 (Fig. 1A) . As expected, FLAG-R6 signal was absent in cells transfected with EV. Next, we investigated the interaction between muscle-specific AMPKβ2 heterotrimers (myc-α1, β2-mCherry, γ1) and R6 (FLAG-R6) using co-transfection and immunoprecipitation in HEK293T. As both proteins coimmunoprecipitated, this data points to the occurrence of a physical interaction between R6 and AMPKβ2 (Fig. 1B) . Interestingly, co-immunoprecipitation appeared stronger in the presence of the AMPKβ2 compared to β1. These data were further confirmed by yeast-two-hybrid (Y2H) analyses: in Fig. 1C it is shown that R6 binds to both AMPKβ1 and β2, while the interaction between AMPKβ2 and R6 is significantly stronger than the one between AMPKβ1 and R6. Combined, these findings suggest that R6 prefers interaction with AMPKβ2 over AMPKβ1.
R6 interaction with AMPKβ2 requires its substrate-binding motif
Recently, a number of functionally distinct protein domains have been identified in the R6 glycogentargeting subunit of PP1 (23) . R6 is composed of domains that mediate binding to carbohydrates (via its CBM), binding to the PP1 catalytic subunit (PP1c; RVXF motif), and to the glycogen metabolism-related substrates of PP1 (via the highly conserved WDNND motif). To investigate whether and which of these motifs are involved in the interaction between the AMPKβ subunit and R6, we performed studies in HEK293T cells co-expressing AMPKβ2 complex (myc-α1, β2-mCherry, γ1) with FLAG-R6, the latter carrying various mutations corresponding to its protein motifs (23) (Fig. 2A, B) . We again immunoprecipitated myc-AMPKα1 using a myc-directed antibody. Of note, endogenous R6 was not detected either in lysate or in immunoprecipitated material, thereby substantiating the need for FLAG-R6 overexpression to study the interaction between AMPKβ2 and R6 ( Fig. 2B : EV condition). R6 carried various domain-specific mutations: in both R6-RARA and R6-RAHA mutants, the hydrophobic valine and phenylalanine residues within putative R6-RVXF motifs were substituted for alanine, allowing us to probe the role of the PP1-binding motif in AMPKβ2/R6-binding (Fig. 2B ). R6-RARA, a mutant known to have lost its capacity to bind to endogenous PP1c but not to PP1-substrates (23) , presented a similar AMPKβ2-binding profile compared to wild-type, non-mutated R6 (R6-WT; Fig. 2B ; right panel). The R6-RAHA mutant that carried mutations in a domain close to the substrate-binding motif, however, had completely lost its ability to interact with AMPK ( Fig. 2B ; right panel). This data was reproduced in a reciprocal Y2H assay using AMPKβ2 as bait (Fig. 2C) . Further, the substrate-binding motif (WDNND) was mutated to study its effect on AMPKβ2/R6 interaction. In one of the mutants, the two aspartate residues present within the WDNND motif were replaced by alanine (R6-WANNA mutant), whereas in the R6-WDNAD mutant, the second asparagine residue was replaced by alanine. Whereas the R6-WDNAD mutant was still capable of interacting with AMPKβ2, the WANNA mutation abolished AMPKβ2 binding ( Fig. 2B right panel and 2C). In good agreement, Y2H analyses using AMPKβ1 or AMPKβ2 as bait confirmed that the binding of R6 to the AMPKβ subunits depended on the R6 substratebinding motif being intact ( Fig. 2C and 2D ). Thus, we show that the AMPKβ/R6 interaction requires the R6 substrate-binding motif. In all subsequent experiments, we concentrated on AMPKβ2/R6 interaction.
AMPKβ2 Thr-148 mutant shows reduced interaction with R6
Previously, we showed that substitution of the glycine-147 residue for arginine (G147R) within the β1-CBM domain abolished the interaction of AMPK with R6 (20), indicating that AMPKβ1 requires the CBM for interaction with R6. More recently, we demonstrated that autophosphorylation at the β-threonine-148 (Thr-148) residue, centrally located in the CBM, prevents AMPK from binding to carbohydrates such as glycogen (22) . As we show here that R6 also interacts with AMPKβ2, we next investigated whether Thr-148 is required for AMPKβ2/R6 interaction. To this end, a phospho-mimicking AMPKβ2 mutant was generated by substituting the threonine-148 residue for aspartate (T148D) within the β2-CBM. Transiently transfected HEK293T cells co-expressing FLAG-R6 and AMPK heterotrimers (myc-α1 and γ1 in combination with either β2-WT-or β2-T148D-mCherry), were cultured under high glucose conditions (25 mM) and used for co-immunoprecipitation analysis. Impaired interaction between AMPKβ2 and R6 was observed in cells overexpressing mutant AMPKβ2-T148D ( Fig. 3A ; right panel); relevantly, FLAG-R6 and mCherry-β2 were expressed at comparable levels ( Fig. 3A ; left panel). Independent Y2H analyses corroborated these findings: T148D mutation decreased the interaction between AMPKβ2 and R6 ( Fig. 3B ). Taken together, our data indicate that Thr-148 mutation into aspartate results in loss of AMPKβ2/R6 interaction, suggesting that an intact Thr-148 residue is essential for the formation of the AMPKβ2/R6 complex under glucose-rich culturing conditions.
Glycogen depletion enhances the interaction between AMPKβ2 and R6
To investigate whether the interaction between AMPKβ2 and R6 is responsive to variation in glycogen level, we aimed to deplete cellular glycogen content. Hence, HEK293T cells were either pharmacologically treated with forskolin, a compound inducing glycogen breakdown (31), or glucosedeprived, after which glycogen content was assessed. Because R6 is known to have glycogenic properties (24), we included non-transfected control cells and compared these with cells that were either transfected with FLAG-R6 alone, or co-transfected with all three subunits of AMPK (myc-α1, β2-WT-mCherry, γ1).
As expected, cells overexpressing FLAG-R6 showed high glycogen content (both in the absence and presence of overexpressed AMPKβ2 complex): basal glycogen levels were 30 − 40-fold increased compared to non-transfected control cells (Fig. 4A ). Both forskolin-treatment and glucose-deprivation significantly lowered the intracellular glycogen levels in all cell lines, as compared to control (Fig. 4A) .
To assess the effect of cellular glycogen content on AMPKβ2/R6 interaction, HEK293T cells overexpressing both FLAG-R6 and AMPKβ2 heterotrimers were either treated with forskolin or glucosedeprived for 16 h. Reduction of cellular glycogen content, either by forskolin-treatment or glucosedeprivation, substantially enhanced the interaction between AMPKβ2 and R6 that was accompanied by a similar increase in the T172 phosphorylation level ( Fig. 4B ; right panel); as total levels of AMPK and R6 did not change within the experimental time frame ( Fig. 4B ; left panel), this ruled out any possible interference by altered expression. Further, we examined whether the binding of overexpressed AMPKβ2 to FLAG-R6 is reversible (Fig. 4C) . Expectedly, immunoprecipitates of AMPK from cells that were cultured in low glucose medium displayed clear interaction with R6. When cells were switched back to incubation in high glucose medium this association decreased time-dependently resulting in a complete loss of the AMPKβ2/R6 interaction after 30 minutes. Collectively, our data suggest that the interaction between AMPKβ2 heterotrimers and R6 is dynamic and inversely correlated to cellular glycogen level.
To independently examine a possible direct effect of glycogen on the AMPKβ2/R6 binding, we next used β-cyclodextrin (β-CD), a model-sugar that mimics glycogen, in competitive bindingimmunoprecipitation experiments in HEK293T cells cultured under high glucose. Addition of β-CD completely disrupted the interaction between AMPKβ2 and R6 ( Fig. 4D; right panel) . Combined, these data suggest that under glucose-rich conditions glycogen disturbs AMPKβ2/R6 interaction, indicating that glycogen interferes with and therefore weakens the interaction between AMPKβ2 and R6.
AMPKβ2/R6 interaction is enhanced by glycogen depletion in conjunction with increased AMPKβ2 Thr-148 phosphorylation Next, we assessed the impact of Thr-148 phosphorylation on the glycogen-modulated AMPKβ2/R6 interaction. To this end, we co-transfected HEK293T cells with AMPK heterotrimers (myc-α1, γ1, and either mCherry-tagged β2-WT or -T148D mutant) and FLAG-R6, and challenged the cells for 16 h with various concentrations of glucose. The expression of AMPKβ2-T148D mutant did not affect the glycogenic activity of FLAG-R6 in cells cultured under high glucose conditions (Fig. 5A ), indicating that glycogen production depends on the function of R6 but not on the interaction between R6 and AMPKβ2. Reduced availability of glucose (i.e., 3 mM or 0 mM) correlated with significantly decreased intracellular levels of glycogen in both AMPKβ2-WT and -T148D expressing cells (Fig. 5A) . Interestingly, we observed increased levels of Thr-148 phosphorylation in β2-WT immunoprecipitates upon lowering glucose conditions, although we did not find changes in the levels of AMPK Thr-172 phosphorylation, neither in cellular lysates nor in the precipitates from β2-WT or β2-T148D expressing cells (Fig. 5B) . Low glycogen content enhanced AMPKβ2/R6 interaction ( Fig. 5B; cf. Fig. 4 ). Whereas AMPKβ2-WT/R6 binding was readily detectable, T148D mutation completely abolished AMPKβ2 interaction with R6, independent of the glycogen status ( Fig. 5B; cf. Fig. 3 ). Further, we investigated the effect of AMPK activation on AMPKβ2/R6 interaction using various AMPK activating stimuli (Fig. 5C ). Again, AMPKβ2-T148D mutant did not associate with R6 in any of the conditions tested. AMPK activation generally enhanced AMPKβ2-WT/R6 interaction. Oligomycin exhibited the strongest AMPK activating effect (Thr-172 phosphorylation in Fig. 5C ; left panel). AMPKβ2 Thr-148 phosphorylation and the binding of R6 to AMPKβ2 were greatly enhanced by oligomycin ( Fig. 5C; right panel) . Next, we exposed cells to oligomycin in the context of high and low cellular glycogen. If glycogen content was low (i.e., 3 mM glucose), oligomycin activated AMPK (Thr-172 phosphorylation; Fig. 5D ), an effect that was overruled by high cellular glycogen content (i.e., 25 mM glucose). Oligomycin-induced activation of AMPK and the consequential Thr-148 phosphorylation further enhanced the interaction of AMPKβ2-WT and R6 ( Fig. 5D; right panel) under low glycogen conditions. This interaction was disrupted by high cellular glycogen or by T148D mutation (Fig. 5D) . These results indicate that glycogen-depletion enhances both AMPKβ2/R6 interaction and phosphorylation of Thr-148. Our data also indicate that phosphorylation of AMPKβ2 at Thr-148 has a different outcome from AMPKβ2-T148D mutant: whereas the AMPKβ2-T148D mutant is not able to interact with R6, AMPKβ2/R6 interaction is improved under conditions that enhance AMPKβ2 Thr-148 phosphorylation.
Endogenous AMPKβ2 shows enhanced interaction with R6 upon glycogen depletion in C2C12 myotubes Furthermore, we explored the significance of cellular glycogen with respect to AMPKβ2/R6 interaction in C2C12 myotubes, a more physiologically relevant model. Similar to all other tested cell types, endogenous R6 was below detection level in C2C12 cells using a variety of available antibodies (data not shown). Hence, we stably expressed FLAG-R6 or empty vector (EV) control in C2C12 myoblasts. C2C12 cells were then differentiated to myotubes and cultured under high (i.e., 25 mM) or low (i.e., 3 mM) glucose concentrations prior to oligomycin-treatment. We determined glycogen content and AMPKβ2/R6 interaction for each condition (Fig. 6A, B) . Both lowered glucose availability and oligomycin-treatment reduced the myocellular glycogen content below detection level in cells expressing the EV control (Fig.  6A) . R6 overexpression greatly enhanced the levels of glycogen under basal and treated conditions (Fig.  6A) . Oligomycin challenged the glycogen levels (Fig, 6A) and clearly induced AMPK activation in C2C12 myotubes, under both high and low glucose conditions (Fig 6B, left panel) . However, as in HEK293T cells, oligomycin-mediated AMPK activation could only be detected in immunoprecipitates from cells that were cultured under low glycogen conditions ( Fig. 6B; right panel) . As expected, increased interaction of AMPKβ2 with R6 was detected after immunoprecipitating FLAG-R6 from oligomycintreated cells under low glycogen conditions ( Fig. 6B; right panel) . By performing the reverse immunoprecipitation using AMPKα1/α2-directed antibodies, we also detected enhanced FLAG-R6 presence in the low glycogen condition (Fig. 6C) . Moreover, we detected T148-phosphorylation of endogenous AMPKβ2, which expectedly was highest in conjunction with low glycogen in oligomycintreated immunoprecipitates (Fig. 6C) . We further assessed the presence of Thr-148 phosphorylation in a physiological context. Gastrocnemius muscle was obtained from untreated mice and AMPK was immunoprecipitated from homogenates (Fig. 6D) . As shown by Western blotting, Thr-148 phosphorylation signal was evident. Decrease of this signal upon incubation with calf intestine phosphatase (CIP) further confirms the phosphorylation event. Therefore, skeletal muscle may operate signaling pathways involving phosphorylated Thr-148. Taken together, in good agreement with our observations in HEKT293 cells, the data obtained from C2C12 myotubes support the notion that cellular glycogen content controls AMPKβ2/R6 binding. Also, Thr-148 phosphorylation of endogenous AMPKβ2 occurred in conjunction with R6 interaction in C2C12 myotubes
AMPKβ2 Thr-148 mutant enhances glycogen content of C2C12 myotubes
We next studied the effect of expressing AMPKβ2-T148D mutant in C2C12 cells in terms of glucose uptake and glycogen accumulation. To this end, we stably expressed AMPKβ2-WT or -T148D mutant in C2C12 cells, and after differentiation, cells were incubated in high, low or absence of glucose. Expectedly, the glycogen levels were challenged by low or no glucose incubations (Fig. 7A) . However, relative to WT, the T148D mutant overexpressing cells showed higher glycogen content (under high glucose). Since AMPKβ2-T148D mutant does not associate with glycogen (and R6), these data could indicate a function of the AMPKβ2-T148D mutant that is independent of the glycogen particle, possibly by improving glucose uptake. However, glucose uptake changes were statistically insignificant (Fig. 7B) .
DISCUSSION
In the current study, we demonstrate the involvement of Thr-148 in the dynamic AMPKβ2/R6 interaction that is governed by glycogen content.
Due to the positioning of Thr-148 in the carbohydrate-binding pocket, the phosphorylation of this residue is incompatible with glycogen binding Glucose deprivation expectedly resulted in reduced glycogen levels (Figs. 4-7) . Accordingly, we detected strong AMPKβ2 Thr-148 phosphorylation signals only when glycogen levels were low, which were further augmented by oligomycin treatment (Fig. 5) . Similar to GS, which dissociates from glycogen in response to glycogen breakdown (32, 33) , decreased glycogen content may also cause AMPKβ2 and R6 to leave glycogen. In support of such notion, oligomycin-induced AMPK activation augmented AMPKβ2/R6 interaction also in C2C12 myotubes, while further depleting glycogen and inducing Thr-148 phosphorylation (Fig. 6) , strongly suggesting that these events are linked. In conjunction with lowered glycogen content, oligomycin-induced Thr-172 phosphorylation was also more effective, which ties in with autophosphorylation of Thr-148, i.e., by AMPK. Thus, autophosphorylation of Thr-148 by AMPK may indicate detachment of AMPK from glycogen in conditions that challenge the cellular glycogen level.
We find that phosphorylation of AMPKβ2 at Thr-148 enhanced the binding to R6, whereas AMPKβ2/R6 interaction was completely lost in the AMPKβ2-T148D mutant. The latter results are in agreement with earlier observations, where the AMPKβ1-G147R mutation impaired the ability to interact with R6 (20). Since AMPKβ Thr-148 is located adjacent to Gly-147, a similar loss of binding to R6 for the Thr-148 mutant was expected. Nevertheless, the molecular mechanism explaining the loss of binding to R6 as a result of T148D mutation remains unclear, because Thr-148 phosphorylation was enhanced in conjunction with AMPKβ2/R6 interaction (Fig. 5) . In our previous study, we found that T148D mutant did not bind glycogen (22) . Hence, there are at least two possible explanations: (i) the T148D mutation causes a subtle modification in the conformation of the β2 subunit resulting in the loss of interaction with R6, a process not shared by the physiological phosphorylation of this subunit; or (ii) the interaction of AMPKβ2-WT with R6 that is observed during glycogen degradation evolves from their initial binding at glycogen. These explanations are not mutually exclusive and we formally cannot rule out the former, but there are arguments in support of the latter notion. Firstly, both AMPKβ2 and R6 bind to glycogen via their respective CBM (12, 34) . The co-localization of AMPK and R6 to glycogen brings them in close proximity to each other, which may facilitate their subsequent direct interaction, i.e., as a second step during conditions that degrade glycogen. Hence, the possible mechanisms causing AMPKβ2 and R6 to leave the dwindling glycogen particle may include the decreasing surface binding options. On a diminishing glycogen granule, we can indeed expect the concentration of potential interaction partners to increase dramatically, which may facilitate a direct binding between these proteins concomitant with their detachment from glycogen. This is in accordance with our findings showing that depletion of intracellular glycogen resulted in enhanced AMPKβ2/R6 interaction (Figs. 4-6 ). In particular, the AMPKβ2/R6 complex was more abundant in glucose-deprived or forskolin-treated cells (Fig. 4B) . Similarly, in earlier Y2H analyses, low glucose media augmented the AMPKβ1/R6 interaction (35) . Secondly, high glycogen content was found to decrease AMPKβ2/R6 interaction (Figs. 4-6) , and thus glycogen may in fact rather perturb the direct binding between AMPKβ2 and R6. In addition, AMPKβ2/R6 binding decreased upon treatment of co-immunoprecipitations with β-CD (Fig. 4D) . Since the R6-substrate-binding motif partially overlaps with the CBM domain (23) , it is conceivable that glycogen competes with R6 binding to AMPK. Thus, our data suggest that low glycogen favors AMPKβ2/R6 interaction, whereas high glycogen content interferes with it. We propose that the AMPKβ2-T148D mutant, due to lack of glycogen-binding affinity, is excluded from the interaction with R6 because this process initiates at glycogen.
AMPK plays an essential role in various biological processes involved in restoring cellular energy homeostasis. Tuning of such processes requires adequate regulation, and involves AMPK compartmentalization and complex formation with other proteins and substrates. In the present study, we show that R6 preferentially interacts with AMPKβ2, rather than AMPKβ1, pointing to a possible role for this interaction in skeletal muscle. The CBM domain of AMPKβ2 possesses higher binding affinity for carbohydrates such as glycogen than β1 (14) . In a more detailed study the CBM domain of AMPKβ2 bound linear carbohydrates and single α1,6-branched carbohydrates 4-30 fold tighter in comparison with β1 (36). AMPKβ2, as well as R6, are highly expressed in skeletal muscle (3, 37) , a tissue active in controlling disposal of glucose into glycogen (38) . Thus, it is likely that these proteins contribute to the regulation of myocellular glycogen turnover. Recent in vivo studies seemingly contradict the importance of AMPKβ2 in glycogen metabolism: The observed differences in glycogen content were marginal between WT and AMPKβ1/β2 double knockout mice pre-and post-exercise (39) . In AMPKβ2 knockout mice, muscular glycogen content was reduced pre-exercise and was equal with a slight tendency to increase post-exercise (6, 7). However, since there is a reduction in the levels of skeletal muscle AMPKα1 and α2 in β2 knockout mice and a dramatic reduction of the levels of the AMPK complex subunits in double AMPKβ1/β2 knockout mice, it is difficult to make any correlation between the levels of glycogen in these mice and the activity of AMPK. We recently showed that activation of AMPK precedes AMPKβ Thr-148 autophosphorylation to preclude the AMPK complex from binding to glycogen and further data suggested a possible role for Thr-148 phosphorylation in glycogen turnover in several cell lines (22) . Thus, independent of possible functions for AMPK complexes that are bound at glycogen particles, free cytosolic AMPK may also indirectly affect glycogen metabolism, as further supported by T148D overexpression in C2C12 myotubes ( Figure 7) . Moreover, R6 is a known glycogen-binding protein and PP1-targeting subunit acting as a glycogenic driver (24) . Hence, it is conceivable to expect that AMPKβ2/R6 interaction is playing an important role in glycogen metabolism in muscle.
In yeast, it was reported earlier that Gal83 (Snf1 β-subunit ortholog) is involved in binding to Reg1 (PP1 glycogenic subunit ortholog) and studies in mouse pancreatic β cells revealed that AMPKβ1 interacts with the PP1-glycogen targeting subunit R6 (20, 40). R6 recruits PP1 phosphatase to its substrates (e.g., GS and GP) (23), thus playing a critical role in the regulation of glycogen metabolism. Most of the PP1-glycogen-targeting subunits exert their actions through binding to PP1 via a conserved Nterminal PP1-binding motif (RVXF), and interact with PP1-substrates via a conserved C-terminal substrate-binding (WXNXGNYX(L/I)) motif (23) . We have recently shown that R6 utilizes this conserved region to bind to its glycogenic substrates GS and GP (23) . In line with these results, our work indicates that AMPKβ/R6 interaction occurs also via the R6 substrate-binding motif (Fig. 2) , as a mutation in this domain resulted in loss of interaction, a process that is independent of PP1 binding. However, we did not find evidence for R6/PP1-dependent AMPK dephosphorylation in our study under conditions where AMPKβ2/R6 interaction was enhanced. This may be attributed to the use of glycogen depletion and mitochondrial poisoning as triggers. Although we find these treatments as required to induce significant AMPKβ2/R6 interaction, their application necessarily goes along with elevated AMP levels and consequent protection from Thr-172 dephosphorylation (41) . In MIN6 pancreatic β-cells, the R6/PP1 complex was responsible for AMPK dephosphorylation at Thr-172 in response to high extracellular glucose (20) . In HEK293 cells, we find that glucose re-availability leads to a transient decrease of Thr-172 phosphorylation (Fig. 4C) . In the same experiment, AMPKβ2/R6 interaction disappeared timedependently after recovery with high glucose. Hence, the idea that R6 could act as a scaffold to bring AMPKβ2 in close proximity to the PP1 phosphatase warrants further investigation. The present data establish that AMPKβ2/R6 complex formation and dissociation are reversible and dynamic processes that involve the substrate-binding site of R6. Taken together, we shed new light on the molecular events that govern the interaction of AMPK with R6. (myc-α1, γ1, AMPKβ2-mCherry) (B) . FLAG empty vector (EV) was used as control. Cells were continuously cultured under high glucose (25 mM) conditions and harvested 56 h post-transfection. Interaction between AMPKβ1/2 and R6 was assessed by immunoprecipitating the heterotrimeric AMPK complex from 800 μg of lysate using the anti-myc-tag antibody. Western blots were assessed using the indicated antibodies. Representative Western blots are shown. A and B) HEK293T cells either non-transfected, transiently transfected with FLAG-R6 alone, or cotransfected with FLAG-R6, myc-α1, γ1 and mCherry-tagged AMPKβ2-WT were cultured under high glucose (25 mM) conditions. Prior to lysis, cells were treated with forskolin (100 μM) or DMSO (control) under high glucose conditions, or cells were glucose-deprived (GD, 0 mM) for 16 h. (A) Intracellular glycogen level was determined as described in the section Materials and Methods. Levels were corrected for corresponding protein concentrations. * p<0.05 vs. corresponding DMSO controls; n=2. (B) Heterotrimeric AMPK was immunoprecipitated from 500 μg of lysate using the anti-myc-tag antibody, followed by Western blot analysis using the indicated antibodies. (C) HEK293T cells transiently transfected with FLAG-R6, myc-α1, γ1 and mCherry-tagged AMPKβ2-WT were cultured under low glucose (3 mM) conditions and recovered with high glucose medium for the indicated time period before lysis and immunoprecipation. (D) HEK293T cells were transiently co-transfected as indicated and harvested 56 h post-transfection. Cells were continuously grown under high glucose (25 mM) conditions. β-Cyclodextrin (β-CD; 5 mM) was added prior to immunoprecipitation. Representative Western blots are shown. . Endogenous AMPKβ2 shows enhanced interaction with R6 upon glycogen depletion in C2C12 myotubes C2C12 cells stably overexpressing FLAG-R6 were differentiated into myotubes for 4-5 days, and subsequently incubated with high (25 mM) or low (3 mM) glucose for 16 h, followed by 30 minutes treatment with oligomycin (5 μM) or DMSO (control). pBabe-puromycin empty vector (EV) was used as control. (A) Myocellular glycogen levels were determined using biochemical glycogen assay, as described in Materials and Methods. * p<0.05, ** p<0.01, *** p<0.001; n=3. (B) Interaction between AMPKβ2 and R6 was assessed by immunoprecipitation using the anti-FLAG-tag antibody, followed by Western blot analysis using the indicated antibodies. (C) Interaction between AMPKβ2 and R6 was assessed by immunoprecipitation using anti-AMPKα1/α2 antibodies, followed by Western blot analysis using the indicated antibodies. (D) Mouse gastrocnemius muscle lysate was cleared by centrifugation and subjected to immunoprecipitation using AMPK α1/α2 antibodies. Immunoprecipitates were maintained on ice either untreated or treated with calf intestine phosphatase (CIP) and then probed by Western blotting using indicated antibodies. Representative Western blots are shown. 
